

Management of Perinatal Infection



Management of Perinatal Infections

MANAGEMENT OF PERINATAL INFECTIONS

Editors' Note	4
<i>Chlamydia trachomatis</i>	5
Cytomegalovirus	9
Enterovirus	15
Group B streptococcus	19
Hepatitis B virus	25
Hepatitis C virus	1
Herpes simplex virus	7
Human immunodeficiency virus	4
Listeria	51
<i>Mycobacterium tuberculosis</i>	55
<i>Neisseria gonorrhoeae</i>	61
Parvovirus	65
Rubella	71
Syphilis (<i>Treponema pallidum</i>)	77
<i>Toxoplasma gondii</i>	8
Varicella zoster virus	89
Zika virus	97


Chla



CHLAMYDIA – ALGORITHM 2


MANA EMENT F A NE NATE EXP SED T C AMYDIA TRAC MATIS INFECTI N

- Infants born to mothers with untreated C.




CHLAMYDIA TRACH MATIS APPENDIX AND RE ERENCES

1. RANZCOG. Routine antenatal assessment in the absence of pregnancy complications (C-Ob 3b). 2022. <https://ranz cog.edu.au/wp-content/uploads/2022/05/Routine-antenatal-assessment-in-the-absence-of-pregnancy-complications.pdf>
2. <https://sti.guidelines.org.au/sexually-transmissible-infections/chlamydia/>
3. <https://sti.guidelines.org.nz/infections/gonorrhoeal/>
4. <https://kiry.unsw.edu.au/report/asr2018>
5. <https://www.esr.cri.nz/our-services/consultancy/public-health/sti/>
6. Hoover KW, Tao G, Nye MB



CYTOMEGALOVIRUS – ALGORITHM 3

RIS ESTIMATES FOR FETAL TRANSMISSION




COMMENTS

a. Primary MV

CYTOMEGALOVIRUS – ALGORITHM 4

NEONATAL DIAGNOSIS AND MANAGEMENT^{1,35}



CYTOMEGALOVIRUS REFERENCES

References

1. Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. *The Lancet Infectious Diseases* 2017; 17(6): e177-e88.
2. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. *Reviews in Medical Virology* 2007; 17(5): 355-63.
3. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. *Rev Med Virol* 2007; 17(4): 253-76.

4 days before final Bump Cerv - M

Entero

ENTER VIRUS AND PARECH VIRUS – PERINATAL IN ECTI N

Enteroviral infections generally cause insignificant illness, and perinatal transmission of enteroviruses leading to significant symptomatic disease in infants is rare. There are case reports of stillbirth related to maternal and/or fetal infection with coxsackieviruses, echoviruses, and enterovirus 71.

Cases of congenital anomalies such as urogenital anomalies, gastrointestinal tract anomalies, cardiovascular defects and pulmonary hypoplasia have also been described after maternal and/or fetal infection with e

Newborn infections

Enterovirus

- Wide spectrum of clinical presentations, from non-specific febrile illness to fatal multisystem disease
- Fever, irritability, poor feeding, lethargy
- Maculopapular rash in 50%
- Respiratory symptoms in 50%
- Gastrointestinal symptoms in 20%
- Hepatitis in 50%
- Myocarditis, meningoencephalitis

HPV

- Often asymptomatic or mild symptoms including gastroenteritis or influenza-like illness.
- Fever, irritability +/- diffuse rash (described as "red, hot and angry" babies)
- Meningoencephalitis
- Sepsis-like presentation (incl. septic shock)
- Signs of surgical abdomen (uncodilation)
- Adverse neurodevelopmental outcomes seen in 15–20%

Diagnosis

- Tissue culture is slow and requires expertise; it is now rarely used
- Serology is insensitive
- RT-PCR – rapid, sensitive and specific – separate assays are available for enterovirus and parechovirus
- Isolation from stool is highly sensitive but not specific as virus is shed in stool for several weeks
- Detection in blood, CSF and tissue is most reliable as follows:
 - Diagnosis in pregnancy - blood, amniotic fluid, stool
 - Diagnosis in neonate - blood, CSF +/- stool
- Genotyping is possible by PCR sequencing of structural protein genes
- CSF pleocytosis and elevated CSF protein appear to occur more commonly in enterovirus infection than parechovirus infection

Treatment in newborns

- Although there is evidence for safety and possible efficacy of two antiviral agents, pleconaril and pucapavir, neither are currently available
- IVIG may be of benefit – one small RCT showed subtle clinical benefits and faster resolution of viraluria¹


Prevention

- Nursery epidemics have been described
- Handwashing/infection control contact precautions
- Prophylactic IVIG may reduce disease severity in some exposed neonates

Group B


GROUP B STREPTOCOCCUS (GBS) – ALGORITHM 1

MANAGEMENT OF PREGNANCY WITH RESPECT TO GBS INFECTION



GROUP B STREPTOCOCCUS -

MANAGEMENT F INFANT AT RISK F GBS SEPSIS



COMMENTS

- GBS has been cultured from breast milk, but the role of infected breast milk in neonatal infection is uncertain. It is difficult to make

RUP B STREPT C CCUS RE ERENCE S


1. A

Hepatitis B virus

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES


HEPATITIS B VIRUS – A GORITHM 1

MATERNAL DIAGNOSIS AND ASSESSMENT



HEPATITIS B VIRUS - ALGORITHM 2


ANTENATAL MANAGEMENT OF HEPATITIS B INFECTION



H


HEPATITIS C VIRUS – ALGORITHM 1

ANTENATAL DIAGNOSIS FOR HEPATITIS C




HEPATITIS C VIRUS – ALGORITHM 2

ANTENATAL MANAGEMENT OF HEPATITIS C INFECTION




HEPATITIS C VIRUS – ALGORITH




Herpes

HERPES SIMPLE VIRUS (HSV) – ALGORITHM 1


GENITAL V IN PREGNANCY: RI F M T ER T C ILD TRAN MI I N (MTCT)






HERPES SIMPLE VIRUS – ALGORITHM 3

MANAGEMENT F ASYMPT MATIC NE NATE B RN T M T ER WIT ACTIVE GENITA ERPES^a
AT DE IVERY



HERPES SIMPLE VIRUS – ALGORITHM 4

SV INFECTIONS IN PREGNANCY: NEONATAL MANAGEMENT



COMMENTS

- a. Oral aciclovir therapy is not recommended for therapeutic or pre-emptive treatment of HSV in the neonate. The role of oral valaciclovir has not been evaluated in this context.
- b. There are few data to guide management of herpes recurrence after neonatal HSV disease. Most expert recommend performing investigation for HSV disease including LP and HSV PCR and treating empirically with IV aciclovir for the following: herpes recurrence (

HERPES SIMPLEX VIRUS REFERENCES


1. Jones CA, Raynes Greenow C, Isaacs D, on behalf of APSU HSV study team and contributors. Population-based surveillance of neonatal HSV infection in Australia (1997-2011). *Clin Infect Dis.* 2014 Aug 15;59(4):525-31.
2. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. *JAMA.* 2003;289(2):203-9, 2003.
3. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labour. *New Engl J Med.* 1991; 324: 1247-52.
4. Brown ZA, Selke A, Zeh J et al. The acquisition of herpes simplex virus during pregnancy. *New Engl J Med,* 1997; 337: 509-15.
5. Arvin AM, Hensleigh PA, Prober CG et al. Failure of antepartum maternal cultures to predict the infant's risk of exposure to herpes simplex virus at delivery. *New Engl J Med.* 1986; 315: 796-800.
6. Hollier LM, Wendel GD Jr, Krafchik AP - (editors) *Practical Approach to the Management of Infants and Children with Infectious Diseases.* 2nd ed. Philadelphia: Lippincott, Raven, 1997.


Human


i

HUMAN IMMUNODEFICIENCY VIRUS (HIV) - ALGORITHM 1

DIAGNOSIS & MANAGEMENT IN PREGNANCY







HUMAN IMMUNODEFICIENCY VIRUS - ALGORITHM 4

HUMAN IMMUNODEFICIENCY VIRUS - ALGORITHM 4

MANAGEMENT F INFANT AT RISK F MTCT IV^(11,12)


HUMAN IMMUNodeficiency VIRUS REFERENCES

1. RANZCOG. Routine antenatal assessment in the absence of pregnancy complications. C-Obs 3b. 2022. <https://ranzco.org.au/wp-content/uploads/2022/05/Routine-antenatal-assessment-in-the-absence-of-pregnancy-complications.pdf>
2. Australian Government Department of Health. Fourth National Sexually Transmissible Infections Strategy. 2018-2022.
3. ASHM. National HIV testing policy. 2017.
4. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. *Aids*. 2008;22(8):973-81.
5. Rollins N, Mahy M, Becquet R, Kuhn L, Creek T, Mofenson L. Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models. *Sex Transm Infect*. 2012;88(2):2012-050709.
6. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. *JAMA*. 2000;283(9):1167-74.
7. White AB, Mirjahangir JF, Horvath H, Anglemyer A, Read JS. Antiretroviral interventions for preventing breast milk transmission of HIV. *Cochrane Database Syst Rev*. 2014(10):CD011323.
8. Coovadia HM, Rollins NC, Bland RM, Little K, Coutoudis A, Bennish ML, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. *Lancet*. 2007;369(9567):1107-16.
9. Bispo S, Chikhungu L, Rollins N, Siegfried N, Newell ML. Postnatal HIV transmission in breastfed infants of HIV-infected women on ART: a systematic review and meta-analysis. *Journal of the International AIDS Society*. 2017;20(1):21251.
10. Flynn PM, Taha TE, Cababasay M, Fowler MG, Mofenson LM, Owor M, et al. Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial. *Journal of Acquired Immune Deficiency Syndromes: JAIDS*. 2018;77(4):383-92.
11. Panel on Treatment of Pregnant Women with HIV

Listeria

LISTERIA – ALGORITHM 2

DIAGNOSIS AND MANAGEMENT OF INFANT AT RISK FOR PERINATAL ISTERI SIS




COMMENTS

- Preterm delivery is common. Mortality rates range from 20-60% in infected neonates born alive.^{2,6}
 - Perinatal listeria infection can present as **early onset disease** (within 7 days of birth, mean 1.5 days) often associated with prematurity


MYCOBACTERIUM TUBERCULOSIS [MTB]-ALGORITHM 1

ANTENATAL DIAGN SIS: MANAGEMENT ↗ PREGNANT W MAN



MYCOBACTERIUM TUBERCULOSIS – ALGORITHM 2

MANAGEMENT F PR VEN MATERNA TB



MY



MYC BACTERIUM TUBERCUL SIS RE ERENCE

1. A

GUIDE TO INTERPRETATION OF THE TST

	LOW RISK	MODERATE RISK	HIGH RISK
No risk factors	<ul style="list-style-type: none">• Ethnic origin from high prevalence population• Locally identified high risk populations• Adult HIV patient with CD4 count >500/mL• Children aged 1-5 years	<ul style="list-style-type: none">• Recent close contact with infectious TB• HIV-infected or other immunosuppression (including steroids, equivalent of >1mg/kg/day for >4 weeks)• CXR: fibrotic changes suggestive of past TB• Children under 1 year	
0-4 mm	Negative	Negative	Negative
5-9 mm	Negative	Negative	Positive
10-14 mm	Negative	Positive	Positive
15 mm	Positive	Positive	Positive


NEISSERIA GONORRHOEAE - ALGORITHM 1

MA AGEME T FAW MA WIT S SPCTED MATER A EISSEIRIA G RR EAE I FECTI

Routine antenatal testing in pregnancy is not recommended¹ but is sometimes done in high risk or high prevalence settings in Australia and New Zealand^{1,2}. Almost all infections are asymptomatic in women.


Risk factors for *N. gonorrhoeae* infection include:

- Age < 30 years
- High risk sexual contacts (e.g. multiple partners, consistent non-use of condoms)
- Sexually active women of reproductive age residing or returning from a high prevalence country
- Aboriginal or Torres Strait Islander or Maori or Pacific peoples population




COMMENTS

- Dual therapy is recommended due to the changing patterns of antimicrobial resistance in *N. gonorrhoeae*
- Urogenital gonococcal infections have been associated with chorioamnionitis, premature rupture of membranes and preterm birth, low birth weight infants, and spontaneous abortions in pregnant women
- The risk of these complications in the setting of gonococcal infection is 2-5 times greater than in uninfected controls
- Transmission of *N. gonorrhoeae* from an untreated infected mother to her baby may occur in 30-50% of cases
- Chlamydia and *N. gonorrhoeae* infections are the commonest STIs in Australia. The prevalence of *N. gonorrhoeae* infections in women of childbearing age in Australia is about 10 times less than *Chlamydia trachomatis* infections (data: <https://data.kirby.unsw.edu.au/> STIs)³ and similarly in NZ⁴



PARVOVIRUS – ALGORITHM 1

RIS ASSESSMENT




COMMENTS

- a. It is not practicable to prevent exposure at home
- b. Exclusion from work of pregnant school teachers or child care workers is **not recommended** during parvovirus epidemics, which are often very prolonged (nor is exclusion of infected children)
- c. Routine antenatal screening is **not indicated**
- d. There is a 50% risk of transmission from an infected mother to her

PARVOVIRUS - ALGORITHM 2

ANTENATAL DIAGNOSIS & MANAGEMENT



COMMENTS

- IgM is detectable within 1-2 weeks of exposure and usually remains detectable for 2-6 months
- Commercial IgM test kits (ELISA or IF):
 - sensitivity: 70-80% overall (100% in adults with arthropathy; lower in children)
 - specificity: 92-97%

PARVOVIRUS – ALGORITHM 3

MANAGEMENT F PR VEN MA



PARV VIRUS

REFERENCES

1. Attwood LO, Holmes NE, Hui L. Identification and management of congenital parvovirus B19 infection. *Prenat Diagn.* 2020;40:1722-1731.
2. Bascietto F, Liberati M, Murgano D, Buca D, Iacovelli A, Flacco M, Manzoli L, Faliari A, Scalia G, D'Antonio F. Outcome of fetuses with congenital parvovirus B19 infection: systematic review and meta-analysis. *Ultrasound Obstet Gynecol.* 2018;52:569-576.
3. Crane J, Mundle W, Boucoiran I; Maternal Fetal Medicine Committee. Parvovirus B19 infection in pregnancy. *J Obstet Gynaecol Can.* 2014;36:1107-1116.
4. de Jong EP, de Haan TR, Kroes AC, Beersma MF, Oepkes D, Walther FJ. Parvovirus B19 infection in pregnancy. *J Clin Virol* 2006; 36:1-7.
5. Enders M, Weidner A, Rosenthal T, Baisch C, Heden L, Söderlund-Venermo M, Hedman K. Improved diagnosis of gestational parvovirus B19 infection at the time of noninvasive fetal hydrops. *J Infect Dis.* 2008;197:58-62.
6. Hafner H, Andre F, 21, 35, 39, FD 3D 29 610 69 fc tf α CF,g & IE P g

Rubella

A U S T R A L

RUBELLA – ALGORITHM 1


DIAGNOSIS OF SUSPECTED MATERNAL RUBELLA INFECTION

Routine antenatal screening (IgG only)^a 1,2,3

- If IgG -ve, prioritise rubella immunisation after delivery
- If IgG +ve at 10 - 15 IU/L: potential risk of reinfection
Consider re-immunisation after delivery
- If > 15 IU/L: re-immunisation not needed

Rubella testing (IgG/IgM)^b because of

- (i) contact with rubella
- (ii) rubella-like illness (fever, erythematous rash)




RUBE A - A GORITHM 2

RUBELLA


RE ERENCE

-
1. Dilech W, Grangeot-Keros L, Vauloup-Fellous C. Standardization of Assays That Detect Anti-Rubella Virus IgG Antibodies. *Clinical Microbiology Reviews*



SYPHILIS (TREPONEMA PALLIDUM) – ALGORITHM 3

INVESTIGATION AND MANAGEMENT FOR INFANTS BORN TO MOTHERS WITH SYPHILIS



* Procaine penicillin (50 mg/kg per dose), IM, daily may be an option if IV access is not feasible.

SYPHILIS (TREP NEMA PALLIDUM) REFERENCES

1. Walker GJA Antibiotics for syphilis diagnosed during pregnancy. Cochrane Database of Systematic Reviews Issue 3 2009
2. Myles TD et al The Jarisch-Herxheimer reaction and fetal monitoring changes in pregnant women treated for syphilis Obstet Gynecol 1999 93(4):631-2
3. Sheffield JS et al. Congenital syphilis after maternal treatment for syphilis during pregnancy. A J Obstet Gynecol 2002 186(3):569-73
4. Alexander JM et al. Efficacy of treatment for syphilis in pregnancy Obstet Gynecol 1999 93(1):5-8
5. Guideline: Syphilis in pregnancy - Queensland Health (first published 2018, as amended 2021) https://www.health.qld.gov.au/__data/assets/pdf_file/0035/736883/g-sip.pdf
6. Workowski KA, Berman LH, Chan PA et al. Sexually transmitted infections treatment guidelines. MMWR Recomm Rep 2011 60(2):1-29


T

TO OPLASMA GONDII - ALGORITHM 1

ANTENATAL EVALUATION


Antenatal screening is not recommended in Australia but some practitioners may, either routinely or on request.^a Antenatal education about prevention should be provided to all women.

Serology done because of symptoms suggestive of acute toxoplasmosis: malaise, fever, conjunctivitis (e.g. cervical)



TOXOPLASMA GONDII – ALGORITHM 3

INVESTIGATION AND MANAGEMENT OF INFANT AT RISK FOR TOXOPLASMOSIS



COMMENTS

- Neonatal screening not often done, but is an alternative to antenatal screening to detect infected infants for treatment⁷
- Proportion of infants infected and severity depends on when maternal infection occurred and if/how treated^{9,10}
- chorioretinitis/retinal scarring; intracranial calcification; hydrocephalus; hepatosplenomegaly; pneumonia; thrombocytopenia; lymphadenopathy; myocarditis and IgM +ve +/or abnormal placenta +/- SF abnormality (PCR +ve). Toxoplasma serology can assist with confirming diagnosis in symptomatic infants when IgM negative¹
- High incidence of long term sequelae (e.g. chorioretinitis) in untreated infants even if asymptomatic at birth - can be reduced by treatment¹²
- Recommended duration of treatment 12 months. Studies to evaluate shorter durations under evaluation in randomized controlled trials^{1,8}
- Dose: pyrimethamine: 1 mg/kg, every 12 hours for 2 days followed by 1 mg/kg daily for 6 months followed


T X PLASMA RE ERENCE


1. Jose G. Montoya and Jack S. Remington Management of Toxoplasma gondii Infection during Pregnancy Clinical Infectious Diseases 2008; 47:554–66
2. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 1999 May 29;353:1829–33
3. Thiébaud R, Leproust S, Chêne G, Gilbert R; SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 369(9556), 115–122 (2007).
4. Wallon M,

Var

VARICELLA ZOSTER VIRUS – ALGORITHM 3

FETA MEDICINE C UNSE ING F WING C IC ENP X IN PREGNANCY






VARICELLA Z STER VIRUS

REF ERENCES

1. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook, Australian Government Department of Health, Canberra, Varicella (chickenpox) immunisationhandbook.health.gov.au/vaccine-preventable-diseases/varicella-chickenpox
2. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices. MMWR 1996;45:1-25.
3. Enders G Mille E. Varicella and herpes zoster in pregnancy and the newborn, In: Arvin AM,

Zika virus

A U S T R A L A S I A N



CZS is a classic pattern of birth defects and disabilities due to intrauterine transmission of Zika⁸

- Severe microcephaly
- Decreased brain tissue with subcortical calcifications
- Common eye abnormalities: macular scarring and retinal focal pigmentation
- Hypertonia
- Joint abnormalities: arthrogryposis, talipes
- Other findings include: dysphagia, seizures, other eye findings (microphthalmia, optic nerve pallor), other brain malformations on neuroimaging (ultrasound or MR)

ZIKA VIRUS

REFERENCES

1. Pettersson, J. H., et al. (2018). "Re-visiting the evolution, dispersal and epidemiology of Zika virus in Asia." *Epidemiol Microbes Infect* 7(1): 79.
- 2.